摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

KYS05055 | 863297-25-0

中文名称
——
中文别名
——
英文名称
KYS05055
英文别名
2-(2-(dimethylamino)-3-phenyl-3,4-dihydroquinazolin-4-yl)-N-(4-nitrobenzyl)acetamide;2-[2-(dimethylamino)-3-phenyl-4H-quinazolin-4-yl]-N-[(4-nitrophenyl)methyl]acetamide
KYS05055化学式
CAS
863297-25-0
化学式
C25H25N5O3
mdl
——
分子量
443.505
InChiKey
HCOLRSVHDDZVKO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    33
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    93.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    KYS05055 在 10% Pd/C 作用下, 以 甲醇 为溶剂, 生成 KYS05056
    参考文献:
    名称:
    T-type Ca2+ channel blockers suppress the growth of human cancer cells
    摘要:
    In order to further clarify the role of T-type Ca2+ channels in cell proliferation, we have measured the growth inhibition of human cancer cells by using our potent T-type Ca2+ channel blockers. As a result, KYS05090, a most potent T-type Ca2+ channel blocker, was found to be as potent as doxorubicin against some human cancer cells without acute toxicity. Therefore, this letter provides the biological results that T-type calcium channel is important in regulating the important cellular phenotype transition leading to cell proliferation, and thus novel T-type Ca2+ channel blocker presents new prospects for cancer treatment. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.06.034
  • 作为产物:
    描述:
    2-nitrocinnamic acid 在 lithium hydroxide 、 硫酸1-羟基苯并三唑盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 、 tin(ll) chloride 、 二溴三苯基膦 作用下, 以 四氢呋喃二氯甲烷乙酸乙酯 为溶剂, 反应 20.0h, 生成 KYS05055
    参考文献:
    名称:
    Synthesis and SAR studies of a novel series of T-type calcium channel blockers
    摘要:
    For the novel, potent, and selective T-type Ca2+ channel blockers, a series of sulfonamido-containing 3,4-dihydroquinazoline derivatives were prepared and evaluated for their blocking actions on T- and N-type Ca2+ channels. Among them, 9c (KYS05064, IC50 = 0.96 +/- 0.22 mu M) was found to be as potent as Mibefradil and also showed the highest selectivity for T-type Ca2+ channel with no effect on N-type Ca2+ channel. (c) 2006 Published by Elsevier Ltd.
    DOI:
    10.1016/j.bmc.2006.01.005
点击查看最新优质反应信息

文献信息

  • US7271260B2
    申请人:——
    公开号:US7271260B2
    公开(公告)日:2007-09-18
  • Synthesis and SAR studies of a novel series of T-type calcium channel blockers
    作者:Seong Jun Park、Sung Jun Park、Min Joo Lee、Hyewhon Rhim、Yoonjee Kim、Jung-Ha Lee、Bong Young Chung、Jae Yeol Lee
    DOI:10.1016/j.bmc.2006.01.005
    日期:2006.5
    For the novel, potent, and selective T-type Ca2+ channel blockers, a series of sulfonamido-containing 3,4-dihydroquinazoline derivatives were prepared and evaluated for their blocking actions on T- and N-type Ca2+ channels. Among them, 9c (KYS05064, IC50 = 0.96 +/- 0.22 mu M) was found to be as potent as Mibefradil and also showed the highest selectivity for T-type Ca2+ channel with no effect on N-type Ca2+ channel. (c) 2006 Published by Elsevier Ltd.
  • T-type Ca2+ channel blockers suppress the growth of human cancer cells
    作者:Jae Ho Heo、Han Na Seo、Yun Jeong Choe、Sujin Kim、Chun Rim Oh、Young Deuk Kim、Hyewhon Rhim、Dong Joon Choo、Jungahn Kim、Jae Yeol Lee
    DOI:10.1016/j.bmcl.2008.06.034
    日期:2008.7
    In order to further clarify the role of T-type Ca2+ channels in cell proliferation, we have measured the growth inhibition of human cancer cells by using our potent T-type Ca2+ channel blockers. As a result, KYS05090, a most potent T-type Ca2+ channel blocker, was found to be as potent as doxorubicin against some human cancer cells without acute toxicity. Therefore, this letter provides the biological results that T-type calcium channel is important in regulating the important cellular phenotype transition leading to cell proliferation, and thus novel T-type Ca2+ channel blocker presents new prospects for cancer treatment. (C) 2008 Elsevier Ltd. All rights reserved.
查看更多